UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2024

Adicet Bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-38359**	**81-3305277**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**
131 Dartmouth Street, Floor 3 Boston, Massachusetts **(Address of Principal Executive Offices)**		**02116** **(Zip Code)**

Registrant's Telephone Number, Including Area Code: (650) 503-9095

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, par value $0.0001 per share	ACET	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On May 10, 2024, Adicet Bio, Inc. (the Company) presented at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) The Company's presentation was posted to the "Presentations & Events" section of the Company's website at investor.adicetbio.com and is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit No.	**Description**
99.1	Adicet Bio, Inc. Presentation, dated May 10, 2024, furnished herewith.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADICET BIO, INC.

Date:	May 10, 2024	By:	/s/ Nick Harvey
		Name:	*Nick Harvey*
		Title:	*Chief Financial Officer*

Adicet Bio

ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Candidate Designed for Multiple Solid and Hematological Cancer Indications



Shon Green, PhD
VP, Nonclinical Development

27th ASGCT Annual Meeting 2024
Baltimore, MD

ADI-270: Designed to address multiple refractory cancers



- CAR utilizes CD27 as the binding domain and contains CD27 and 4-1BB costimulatory domains plus CD3ζ (3rd gen)
- Inactive form of TGFβ receptor II to mitigate the immunosuppressive effects of TGFβ within the tumor microenvironment
- Host vs graft armoring against alloreactive activated CD70+ T cells to increase persistence
- Combines endogenous γδ innate and adaptive mechanisms to recognize and kill malignant cells

Adicet Bio

CD70 is expressed on multiple solid and hematological cancers with limited expression in normal tissues

- High expression in multiple solid and heme malignancies
  - Beyond ccRCC and NPC, multiple solid tumors are of interest when paired with CD70 screening
- Minimal expression on normal tissues (activated lymphocytes)
- Target has clinical safety experience

Solid tumors



Hematological malignancies



Representative images from a normal tissue array stained for CD70



Adicet Bio internal data
ccRCC= Clear cell renal cell carcinoma; NPC= Nasopharyngeal carcinoma

Adicet Bio

ADI-270 highly enriched for Vδ1 and memory phenotype



ADI-270 is highly pure for Vδ1 T cells



ADI-270 expresses T cell memory markers, innate and chemokine receptors, but largely lacks exhaustion-associated markers





ADI-270 is resilient to the inhibitory effects of TGFβ

ADI-270 showed resilience to transcriptional changes driven by TGFβ signaling





ADI-270 maintained proliferation in the presence of TGFβ



ADI-270 maintained cytotoxicity in the presence of TGFβ



CD70-targeting armors ADI-270 against alloreactive host T cells

Proposed MoA for enhanced persistence of ADI-270



ADI-270 persisted in culture with primed alloreactive T cells derived from 3 donors



ADI-270 exhibited potent in vitro cytotoxicity against a range of CD70 levels in a diverse set of solid and heme malignancies





A498, Caki-2, ACHN, 769-P	Renal Cell Carcinoma
THP-1	Acute Lymphoblastic Leukemia
HUT-78	Cutaneous T cell lymphoma
H1975	Non-small cell lung cancer
MM1.S	Multiple Myeloma

ADI-270 retained potent activity in the context of CD70-low tumors compared to clinically relevant CD70-targeting αβ CAR T cell benchmarks





ADI-270 contributed CAR-dependent and CAR-independent mechanisms of tumor targeting







test materials derived from same donor PBMCs

E:T ratio = 1:1, N=2 donors, ****p<0.0001

ADI-270 demonstrated higher innate cytolytic activity against CD70 negative tumor cells compared to CAR-T cell references





***p<0.001, ****p<0.0001

test materials derived from same donor PBMCs

ADI-270 associated with a lower potential for macrophage activation syndrome and CRS compared to αβ CAR T cell benchmarks





test materials derived from same donor PBMCs

ADI-270 did not demonstrate activation-induced off-target toxicity compared to clinically relevant αβ CAR T cell benchmarks





Pre-stimulation | Post-stimulation with ADI-270 | Post-stimulation with αβ CAR-T Refs

A single dose of ADI-270 showed potent regression and sustained systemic anti-tumor activity in ccRCC xenograft models



ADI-270 demonstrated rapid homing, activation and killing kinetics in ccRCC xenografts resulting in tumor and target eradication

A single dose of ADI-270 showed potent efficacy in A498 tumors, rapidly eradicating CD70+ cells







ADI-270 infiltrated and proliferated with effector function as early as Day 3



ADI-270 anti-tumor activity extended to multiple hematologic tumor xenografts associated with lower CD70 expression

A single dose of ADI-270 was administered IV into NSG mice harboring SC tumor xenografts

CD70 expression



MM1.S
(Multiple Myeloma)



HUT-78
(T Cell Lymphoma)



THP-1
(Acute Myeloid Leukemia)



Next steps: ADI-270

- ADI-270 represents potential evolution of γδ CAR T-cell based therapeutics
- CD27-based 3rd gen CAR demonstrated significant potency advantages[1,2,3,4]
- Armoring against TGFβ and alloreactive T cells confirmed and characterized preclinically
- Robust efficacy maintained across multiple relevant tumor models of varying stringency
- Desirable preclinical safety profile with lower potential for CRS and macrophage activation syndrome
- IND submission in ccRCC expected Q2 2024

[1]Shaffer et al., Blood 2011
[2]Acharya et al., Blood 2023
[3]Leick et al., Cancer Cell 2022
[4]Kasap et al., BioRxiv 2024